FDA Approval Alert: The Need-to-Know | Olaparib Plus Abiraterone and Prednisone/Prednisolone in BRCA-Mutated mCRPC

In May 2023, the FDA approved olaparib plus abiraterone and prednisone or prednisolone for patients with BRCA-mutated metastatic castration-resistant prostate cancer as determined by an FDA-approved test.

Andrew J. Armstrong, MD, MSc, spoke about the recent approval of olaparib plus abiraterone acetate and prednisone in patients with BRCA-mutant metastatic castration-resistant prostate cancer.
Approval of Olaparib Combo Impacts SOC in BRCA-Mutant Metastatic CRPC
Video
Jun 1, 2023 6:00 PM
Andrew J. Armstrong, MD, MSc, spoke about the recent approval of olaparib plus abiraterone acetate and prednisone in patients with BRCA-mutant metastatic castration-resistant prostate cancer.
Patients with BRCA-mutated metastatic castration-resistant prostate cancer can now receive treatment with olaparib plus abiraterone/prednisone or prednisolone regardless of homologous recombination repair status following the combination’s approval by the FDA.
FDA Approves Olaparib Combo in BRCA-Mutated mCRPC
Article
May 31, 2023 8:43 PM
Patients with BRCA-mutated metastatic castration-resistant prostate cancer can now receive treatment with olaparib plus abiraterone/prednisone or prednisolone following the combination’s approval by the FDA.